{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T23:37:46Z","timestamp":1787009866256,"version":"build-2736575974"},"reference-count":19,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"3","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2014,5]]},"DOI":"10.1097\/bor.0000000000000059","type":"journal-article","created":{"date-parts":[[2014,3,24]],"date-time":"2014-03-24T23:01:00Z","timestamp":1395702060000},"page":"252-258","source":"Crossref","is-referenced-by-count":19,"title":["Treatment of hereditary autoinflammatory diseases"],"prefix":"10.1097","volume":"26","author":[{"given":"Nienke M.","family":"ter Haar","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joost","family":"Frenkel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"R1-3-20210128","doi-asserted-by":"crossref","first-page":"2499","DOI":"10.1002\/art.38092","article-title":"2013 update of the 2011 American College of Rheumatology recommendations for the treatment of juvenile idiopathic arthritis: recommendations for the medical therapy of children with systemic juvenile idiopathic arthritis and tuberculosis screening among children receiving biologic medications.","volume":"65","author":"Ringold","year":"2013","journal-title":"Arthritis Rheum"},{"key":"R2-3-20210128","doi-asserted-by":"crossref","first-page":"477","DOI":"10.1016\/j.berh.2012.07.002","article-title":"Biological treatment in adult-onset Stills disease.","volume":"26","author":"Pouchot","year":"2012","journal-title":"Best Pract Res Clin Rheumatol"},{"key":"R3-3-20210128","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1016\/j.clim.2013.03.016","article-title":"Monogenic autoinflammatory diseases: concept and clinical manifestations.","volume":"147","author":"Almeida de Jesus","year":"2013","journal-title":"Clin Immunol"},{"key":"R4-3-20210128","doi-asserted-by":"crossref","first-page":"678","DOI":"10.1136\/annrheumdis-2011-201268","article-title":"Treatment of autoinflammatory diseases: results from the Eurofever Registry and a literature review.","volume":"72","author":"TerHaar","year":"2013","journal-title":"Ann Rheum Dis"},{"key":"R5-3-20210128","doi-asserted-by":"crossref","first-page":"1121","DOI":"10.1177\/039463201202500429","article-title":"Pharmacokinetics of colchicine in pediatric and adult patients with familial Mediterranean fever.","volume":"25","author":"Berkun","year":"2012","journal-title":"Int J Immunopathol Pharmacol"},{"key":"R6-3-20210128","doi-asserted-by":"crossref","first-page":"1142","DOI":"10.1016\/j.jpeds.2012.05.047","article-title":"Colchicine is a safe drug in children with familial Mediterranean fever.","volume":"161","author":"Padeh","year":"2012","journal-title":"J Pediatr"},{"key":"R7-3-20210128","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1016\/j.autrev.2012.07.025","article-title":"Incomplete response to colchicine in M694V homozygote FMF patients.","volume":"12","author":"Lidar","year":"2012","journal-title":"Autoimmun Rev"},{"key":"R8-3-20210128","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1016\/j.semarthrit.2013.04.011","article-title":"Evidence-based recommendations for the practical management of Familial Mediterranean Fever.","volume":"43","author":"Hentgen","year":"2013","journal-title":"Semin Arthritis Rheum"},{"key":"R9-3-20210128","doi-asserted-by":"crossref","first-page":"533","DOI":"10.7326\/0003-4819-157-8-201210160-00003","article-title":"Rilonacept for colchicine-resistant or -intolerant familial Mediterranean fever: a randomized trial.","volume":"157","author":"Hashkes","year":"2012","journal-title":"Ann Intern Med"},{"key":"R10-3-20210128","doi-asserted-by":"crossref","first-page":"2091","DOI":"10.1016\/j.clinthera.2012.09.009","article-title":"Long-term efficacy and safety profile of rilonacept in the treatment of cryopryin-associated periodic syndromes: results of a 72-week open-label extension study.","volume":"34","author":"Hoffman","year":"2012","journal-title":"Clin Ther"},{"key":"R11-3-20210128","doi-asserted-by":"crossref","first-page":"2375","DOI":"10.1002\/art.34409","article-title":"Sustained response and prevention of damage progression in patients with neonatal-onset multisystem inflammatory disease treated with anakinra: a cohort study to determine three- and five-year outcomes.","volume":"64","author":"Sibley","year":"2012","journal-title":"Arthritis Rheum"},{"key":"R12-3-20210128","doi-asserted-by":"crossref","first-page":"R64","DOI":"10.1186\/ar4237","article-title":"Treatment of Muckle-Wells syndrome: analysis of two IL-1-blocking regimens.","volume":"15","author":"Kuemmerle-Deschner","year":"2013","journal-title":"Arthritis Res Ther"},{"key":"R13-3-20210128","doi-asserted-by":"crossref","first-page":"1855","DOI":"10.1093\/rheumatology\/kes097","article-title":"Efficacy of interleukin-1-targeting drugs in mevalonate kinase deficiency.","volume":"51","author":"Galeotti","year":"2012","journal-title":"Rheumatology (Oxford)"},{"key":"R14-3-20210128","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1016\/j.clim.2012.09.011","article-title":"Mevalonate kinase deficiency, a metabolic autoinflammatory disease.","volume":"147","author":"van der Burgh","year":"2013","journal-title":"Clin Immunol"},{"key":"R15-3-20210128","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1001\/2013.jamadermatol.717","article-title":"Identification of a homozygous PSTPIP1 mutation in a patient with a PAPA-like syndrome responding to canakinumab treatment.","volume":"149","author":"Geusau","year":"2013","journal-title":"JAMA Dermatol"},{"key":"R16-3-20210128","doi-asserted-by":"crossref","first-page":"513","DOI":"10.1002\/art.37776","article-title":"Clinical and transcriptional response to the long-acting interleukin-1 blocker canakinumab in Blau syndrome-related uveitis.","volume":"65","author":"Simonini","year":"2013","journal-title":"Arthritis Rheum"},{"key":"R18-3-20210128","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1146\/annurev-med-061512-150641","article-title":"IL-1 blockade in autoinflammatory syndromes.","volume":"65","author":"Jesus","year":"2014","journal-title":"Annu Rev Med"},{"key":"R19-3-20210128","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1186\/2050-6511-14-40","article-title":"Anakinra pharmacokinetics in children and adolescents with systemic-onset juvenile idiopathic arthritis and autoinflammatory syndromes.","volume":"14","author":"Urien","year":"2013","journal-title":"BMC Pharmacol Toxicol"},{"key":"R20-3-20210128","doi-asserted-by":"crossref","first-page":"e474","DOI":"10.1542\/peds.2006-1434","article-title":"Colchicine use in children and adolescents with familial Mediterranean fever: literature review and consensus statement.","volume":"119","author":"Kallinich","year":"2007","journal-title":"Pediatrics"}],"container-title":["Current Opinion in Rheumatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/BOR.0000000000000059","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,5,13]],"date-time":"2021-05-13T19:32:05Z","timestamp":1620934325000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/00002281-201405000-00003"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,5]]},"references-count":19,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2014]]}},"URL":"https:\/\/doi.org\/10.1097\/bor.0000000000000059","relation":{},"ISSN":["1040-8711"],"issn-type":[{"value":"1040-8711","type":"print"}],"subject":[],"published":{"date-parts":[[2014,5]]}}}